Literature DB >> 27513888

Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable.

Katrin Christine Asciutto1, Emir Henic2, Lotten Darlin3, Ola Forslund4, Christer Borgfeldt3.   

Abstract

INTRODUCTION: Human papillomavirus (HPV) infection is an objective marker with a high sensitivity for finding cervical dysplasia. The objective of the current study is to investigate whether HPV testing, combined with liquid-based cytology, is reliable as a test of cure after the loop electrical excision procedure (LEEP).
MATERIAL AND METHODS: The LEEP was performed in 330 women for excision of cervical dysplasia. Follow up consisted of HPV testing and liquid-based cytology at six, 12, and 36 months after treatment. Patients with negative co-testing after 6 months were re-examined after 3 years. Patients who tested positive for high-risk HPV and/or dysplasia were followed up 12 months postoperatively.
RESULTS: At 6 months, the co-testing was double negative in 169 of 260 tested cases (65%). A positive high-risk HPV test (n = 40) was associated with cytological abnormalities (p < 0.001). After 3 years, 227 of 275 examined cases (83%) co-tested negative, including 154 patients who had already tested negative at 6 months and 37 cases with viral clearance at 12 months. Of 26 patients with high-risk HPV at the 3-year follow up, six had LSIL findings on liquid-based cytology, but neither HSIL lesions nor glandular atypia or cervical cancer was found. A negative high-risk HPV test showed a negative predictive value for HSIL of 100% (95% CI 99.8-100%).
CONCLUSIONS: Negative co-testing 6 months after LEEP can be considered a reliable test of cure as 3-year follow-up results are consistent with neither HSIL or cancer.
© 2016 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Human papillomavirus; cervical cancer; cervical dysplasia; cervix; conization

Mesh:

Year:  2016        PMID: 27513888     DOI: 10.1111/aogs.12960

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Perceived cervical cancer risk among women treated for high-grade cervical intraepithelial neoplasia: The importance of specific knowledge.

Authors:  Sonia Andersson; Karen Belkić; Selin Safer Demirbüker; Miriam Mints; Ellinor Östensson
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

2.  Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.

Authors:  Riina Aarnio; Ellinor Östensson; Matts Olovsson; Inger Gustavsson; Ulf Gyllensten
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

3.  Role of Colposcopy after Treatment for Cervical Intraepithelial Neoplasia.

Authors:  Annu Heinonen; Maija Jakobsson; Mari Kiviharju; Seppo Virtanen; Karoliina Aro; Maria Kyrgiou; Pekka Nieminen; Ilkka Kalliala
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

4.  Is self-sampling to test for high-risk papillomavirus an acceptable option among women who have been treated for high-grade cervical intraepithelial neoplasia?

Authors:  Sonia Andersson; Karen Belkić; Miriam Mints; Ellinor Östensson
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

5.  Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia.

Authors:  Ellinor Östensson; Karen Belkić; Torbjörn Ramqvist; Miriam Mints; Sonia Andersson
Journal:  Oncol Lett       Date:  2021-01-31       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.